ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
PCSK9 억제제 시장 규모는 최근 급격한 성장을 이루고 있습니다. 2025년 32억 4,000만 달러에서 2026년에는 39억 2,000만 달러에 이르고, CAGR 21.0%로 성장할 전망입니다. 지난 수년간의 성장 요인으로는 PCSK9 억제제 공급 제한, 단일클론항체 치료제에 대한 의존도, 심혈관 질환 위험에 대한 인식 증가, 지질 강하제 처방 증가, 1세대 PCSK9 억제제의 규제 당국 승인 등을 꼽을 수 있습니다.
PCSK9 억제제 시장 규모는 향후 몇 년간 급성장이 전망됩니다. 2030년에는 82억 8,000만 달러에 이르고, CAGR은 20.6%를 나타낼 전망입니다. 예측 기간 동안 성장 요인으로는 인클리시란을 비롯한 siRNA 치료제의 등장, 병용요법 옵션의 확대, 개인 맞춤형 의료 접근법 채택 증가, 심혈관 질환 관리에 대한 의료비 지출 증가, 디지털 환자 모니터링 및 복약 순응도 프로그램 개발 등을 꼽을 수 있습니다. 예측 기간 동안 주요 동향으로는 고콜레스테롤혈증 및 심혈관 질환의 유병률 증가, 피하 및 정맥 투여 경로의 채택 확대, 바이오시밀러 및 병용요법 개발, 개별화된 지질저하 치료에 대한 투자 증가, 전문 클리닉 및 병원 기반 PCSK9 치료 프로그램 확대 등이 있습니다.
고지혈증 유병률 증가는 향후 몇 년 동안 PCSK9 억제제 시장의 성장을 견인할 것으로 예측됩니다. 고지혈증은 혈중 콜레스테롤, 중성지방 등 지질 수치가 높아져 심혈관 질환의 위험을 높이는 상태를 말합니다. 45세 이후 콜레스테롤 수치가 현저하게 상승하는 경향이 있기 때문에 고령화에 따라 그 유병률이 증가하고 있습니다. PCSK9 억제제는 간에서 혈액 내 과도한 LDL 콜레스테롤을 제거하는 능력을 향상시켜 전반적인 지질 프로파일을 개선함으로써 고지혈증 관리에 도움을 줍니다. 예를 들어, 2023년 12월 호주 통계청이 발표한 자료에 따르면, 고콜레스테롤혈증 유병률은 18-34세의 1.1%에서 75세 이상 29.0%로 급격하게 증가했습니다. 따라서 고지혈증 유병률 증가가 PCSK9 억제제 시장의 성장을 견인하고 있습니다.
PCSK9 억제제 시장의 주요 기업들은 고위험 심혈관 질환 환자의 LDL 콜레스테롤을 영구적으로 낮추는 지속적 또는 일회성 치료를 제공하기 위해 생체 내 유전자 치료와 같은 혁신적인 솔루션에 집중하고 있습니다. 생체 내 유전자 치료는 표적 세포 내 결함 유전자를 교정 또는 대체하기 위해 유전물질을 환자의 체내에 직접 도입하여 질병의 근원에서 치료 효과를 발휘하는 방법입니다. 예를 들어, 지난 4월 미국 소재 임상 개발 단계 기업인 Verve Therapeutics Inc.는 헤테로 접합 가족성 고콜레스테롤혈증(HeFH) 및 젊은 관상동맥질환 환자를 대상으로 한 VERVE-102의 1b상 Heart-2 임상 1b상 초기 결과를 보고했습니다. VERVE-102의 단회 투여로 PCSK9 단백질과 LDL 콜레스테롤 수치가 용량 의존적으로 감소했습니다. 0.6 mg/kg 투여군에서 평균 53%의 LDL 콜레스테롤 감소를 보였으며, 일부 피험자에서는 최대 69%까지 감소가 확인되어 강력한 콜레스테롤 저하 치료제로서의 가능성을 보여주었습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 공급망 분석
제4장 세계 시장 동향과 전략
제5장 최종 이용 산업 시장 분석
제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오
제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석
제8장 TAM(Total Addressable Market) 규모
제9장 시장 세분화
제10장 지역별/국가별 분석
제11장 아시아태평양 시장
제12장 중국 시장
제13장 인도 시장
제14장 일본 시장
제15장 호주 시장
제16장 인도네시아 시장
제17장 한국 시장
제18장 대만 시장
제19장 동남아시아 시장
제20장 서유럽 시장
제21장 영국 시장
제22장 독일 시장
제23장 프랑스 시장
제24장 이탈리아 시장
제25장 스페인 시장
제26장 동유럽 시장
제27장 러시아 시장
제28장 북미 시장
제29장 미국 시장
제30장 캐나다 시장
제31장 남미 시장
제32장 브라질 시장
제33장 중동 시장
제34장 아프리카 시장
제35장 시장 규제 상황과 투자환경
제36장 경쟁 구도와 기업 개요
제37장 기타 주요 기업 및 혁신 기업
제38장 세계 시장 경쟁 벤치마킹과 대시보드
제39장 주요 인수합병(M&A)
제40장 시장 잠재력이 높은 국가, 부문, 전략
제41장 부록
LSH
영문 목차
영문목차
PCSK9 inhibitors are medications that lower LDL cholesterol by preventing the PCSK9 protein from degrading LDL receptors on liver cells. By blocking PCSK9, these inhibitors enhance the liver's capacity to remove low-density lipoprotein cholesterol, thereby reducing blood cholesterol levels and lowering the risk of cardiovascular diseases.
The main drug types of PCSK9 inhibitors include alirocumab, evolocumab, inclisiran, bococizumab, and others. Alirocumab is a fully human monoclonal antibody that inhibits PCSK9 to reduce LDL cholesterol levels in patients with hypercholesterolemia. These drugs can be administered orally, subcutaneously, or intravenously, and the modalities include fully human monoclonal antibodies and small interfering RNA (siRNA). They are applied in conditions such as hypercholesterolemia, hyperlipidemia, cardiovascular disease prevention, and familial hypercholesterolemia, and are distributed through hospitals, specialty clinics, retail pharmacies, and online pharmacies.
Tariffs have affected the PCSK9 inhibitor market by increasing costs of imported raw materials, biologics, and active pharmaceutical ingredients used in monoclonal antibodies and siRNA therapies. Segments like fully-humanized monoclonal antibodies and small interfering RNA (siRNA) therapies are most impacted, particularly in North America and Asia-Pacific regions including China and India. This has led to higher treatment costs and potential delays in drug availability. On the positive side, tariffs have encouraged domestic manufacturing, investment in local R&D, and innovation in cost-effective PCSK9 therapies.
The pcsk9 inhibitor market research report is one of a series of new reports from The Business Research Company that provides pcsk9 inhibitor market statistics, including pcsk9 inhibitor industry global market size, regional shares, competitors with a pcsk9 inhibitor market share, detailed pcsk9 inhibitor market segments, market trends and opportunities, and any further data you may need to thrive in the pcsk9 inhibitor industry. This pcsk9 inhibitor market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The pcsk9 inhibitor market size has grown exponentially in recent years. It will grow from $3.24 billion in 2025 to $3.92 billion in 2026 at a compound annual growth rate (CAGR) of 21.0%. The growth in the historic period can be attributed to limited availability of pcsk9 inhibitors, reliance on monoclonal antibody therapies, growing awareness of cardiovascular disease risks, increasing physician prescriptions of lipid-lowering drugs, regulatory approvals for first-generation pcsk9 inhibitors.
The pcsk9 inhibitor market size is expected to see exponential growth in the next few years. It will grow to $8.28 billion in 2030 at a compound annual growth rate (CAGR) of 20.6%. The growth in the forecast period can be attributed to launch of inclisiran and other siRNA therapies, expansion of combination therapy options, increasing adoption of personalized medicine approaches, rising healthcare expenditure on cardiovascular disease management, development of digital patient monitoring and adherence programs. Major trends in the forecast period include rising prevalence of hypercholesterolemia and cardiovascular diseases, increased adoption of subcutaneous and intravenous administration routes, development of biosimilars and combination therapies, growing investment in personalized lipid-lowering treatments, expansion of specialty clinics and hospital-based pcsk9 therapy programs.
The rising prevalence of hyperlipidemia is expected to drive growth in the PCSK9 inhibitor market in the coming years. Hyperlipidemia is a condition marked by elevated levels of lipids, including cholesterol and triglycerides, in the bloodstream, increasing the risk of cardiovascular diseases. Its prevalence is growing due to aging populations, as cholesterol levels typically rise significantly after age 45. PCSK9 inhibitors help manage hyperlipidemia by enhancing the liver's ability to remove excess LDL cholesterol from the blood, improving overall lipid profiles. For example, in December 2023, the Australian Bureau of Statistics reported that high cholesterol rates increase sharply from 1.1% among individuals aged 18-34 to 29.0% in those aged 75 and older. Therefore, the rising prevalence of hyperlipidemia is propelling growth in the PCSK9 inhibitor market.
Key companies in the PCSK9 inhibitor market are focusing on innovative solutions such as in vivo gene therapy to provide long-lasting or one-time treatments that permanently lower LDL cholesterol in high-risk cardiovascular patients. In vivo gene therapy involves delivering genetic material directly into the patient's body to modify or replace defective genes in targeted cells, producing therapeutic effects at the source of disease. For instance, in April 2025, Verve Therapeutics Inc., a US-based clinical-stage company, reported early results from its Heart-2 Phase 1b trial of VERVE-102, targeting patients with heterozygous familial hypercholesterolemia (HeFH) and premature coronary artery disease. A single dose of VERVE-102 led to dose-dependent reductions in PCSK9 protein and LDL-C levels, with the 0.6 mg/kg group experiencing an average LDL cholesterol drop of 53% and some participants reaching a maximum reduction of 69%, highlighting its potential as a powerful cholesterol-lowering therapy.
In March 2024, LIB Therapeutics, a US-based biopharmaceutical company, partnered with Hasten Biopharmaceuticals to commercialize its PCSK9 inhibitor LIB003 in China. Through this partnership, LIB Therapeutics aims to accelerate the clinical development and regulatory approval of lerodalcibep in China by leveraging Hasten Biopharmaceuticals' expertise in the country's regulatory landscape and market dynamics, advancing a novel therapeutic option for patients with hypercholesterolemia. Hasten Biopharmaceuticals Co., Ltd. is a China-based company specializing in clinical development and drug manufacturing, supporting the clinical trial application for lerodalcibep.
North America was the largest region in the PCSK9 inhibitor market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pcsk9 inhibitor market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the pcsk9 inhibitor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The PCSK9 inhibitor market consists of sales of monoclonal antibodies, sirna therapies, small molecule inhibitors, and peptide-based inhibitors. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
PCSK9 Inhibitor Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses pcsk9 inhibitor market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on end user analysis.
Benchmark performance against key competitors based on market share, innovation, and brand strength.
Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for pcsk9 inhibitor ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The pcsk9 inhibitor market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Scope
Markets Covered:1) By Drug Type: Alirocumab; Evolocumab; Inclisiran; Bococizumab; Other Types
2) By Route of Administration: Oral; Subcutaneous Injection; Intravenous Injection
3) By Modality: Fully-Humanized Monoclonal Antibodies; Small Interfering RNA (siRNA)
4) By Application: Hypercholesterolemia; Hyperlipidemia; Cardiovascular Disease Prevention; Familial Hypercholesterolemia
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report
+ Excel Dashboard
Added Benefits
Bi-Annual Data Update
Customisation
Expert Consultant Support
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.
4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
4.2. Major Trends
4.2.1 Rising Prevalence Of Hypercholesterolemia And Cardiovascular Diseases
4.2.2 Increased Adoption Of Subcutaneous And Intravenous Administration Routes
4.2.3 Development Of Biosimilars And Combination Therapies
4.2.4 Growing Investment In Personalized Lipid-Lowering Treatments
4.2.5 Expansion Of Specialty Clinics And Hospital-Based Pcsk9 Therapy Programs
5. PCSK9 Inhibitor Market Analysis Of End Use Industries
5.1 Hospitals
5.2 Specialty Clinics
5.3 Retail Pharmacies
5.4 Online Pharmacies
5.5 Cardiology Centers
6. PCSK9 Inhibitor Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market
7. Global PCSK9 Inhibitor Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis
7.1. Global PCSK9 Inhibitor PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
7.2. Global PCSK9 Inhibitor Market Size, Comparisons And Growth Rate Analysis
7.3. Global PCSK9 Inhibitor Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
7.4. Global PCSK9 Inhibitor Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)
8. Global PCSK9 Inhibitor Total Addressable Market (TAM) Analysis for the Market
8.1. Definition and Scope of Total Addressable Market (TAM)
8.2. Methodology and Assumptions
8.3. Global Total Addressable Market (TAM) Estimation
8.4. TAM vs. Current Market Size Analysis
8.5. Strategic Insights and Growth Opportunities from TAM Analysis
9. PCSK9 Inhibitor Market Segmentation
9.1. Global PCSK9 Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Alirocumab, Evolocumab, Inclisiran, Bococizumab, Other Types
9.2. Global PCSK9 Inhibitor Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific PCSK9 Inhibitor Market, Segmentation By Drug Type, Segmentation By Route of Administration, Segmentation By Modality, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
12. China PCSK9 Inhibitor Market
12.1. China PCSK9 Inhibitor Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
12.2. China PCSK9 Inhibitor Market, Segmentation By Drug Type, Segmentation By Route of Administration, Segmentation By Modality, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
13. India PCSK9 Inhibitor Market
13.1. India PCSK9 Inhibitor Market, Segmentation By Drug Type, Segmentation By Route of Administration, Segmentation By Modality, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
14. Japan PCSK9 Inhibitor Market
14.1. Japan PCSK9 Inhibitor Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
14.2. Japan PCSK9 Inhibitor Market, Segmentation By Drug Type, Segmentation By Route of Administration, Segmentation By Modality, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
15. Australia PCSK9 Inhibitor Market
15.1. Australia PCSK9 Inhibitor Market, Segmentation By Drug Type, Segmentation By Route of Administration, Segmentation By Modality, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
16. Indonesia PCSK9 Inhibitor Market
16.1. Indonesia PCSK9 Inhibitor Market, Segmentation By Drug Type, Segmentation By Route of Administration, Segmentation By Modality, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
17. South Korea PCSK9 Inhibitor Market
17.1. South Korea PCSK9 Inhibitor Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
17.2. South Korea PCSK9 Inhibitor Market, Segmentation By Drug Type, Segmentation By Route of Administration, Segmentation By Modality, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
18. Taiwan PCSK9 Inhibitor Market
18.1. Taiwan PCSK9 Inhibitor Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
18.2. Taiwan PCSK9 Inhibitor Market, Segmentation By Drug Type, Segmentation By Route of Administration, Segmentation By Modality, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
19. South East Asia PCSK9 Inhibitor Market
19.1. South East Asia PCSK9 Inhibitor Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
19.2. South East Asia PCSK9 Inhibitor Market, Segmentation By Drug Type, Segmentation By Route of Administration, Segmentation By Modality, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
20. Western Europe PCSK9 Inhibitor Market
20.1. Western Europe PCSK9 Inhibitor Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
20.2. Western Europe PCSK9 Inhibitor Market, Segmentation By Drug Type, Segmentation By Route of Administration, Segmentation By Modality, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
21. UK PCSK9 Inhibitor Market
21.1. UK PCSK9 Inhibitor Market, Segmentation By Drug Type, Segmentation By Route of Administration, Segmentation By Modality, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
22. Germany PCSK9 Inhibitor Market
22.1. Germany PCSK9 Inhibitor Market, Segmentation By Drug Type, Segmentation By Route of Administration, Segmentation By Modality, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
23. France PCSK9 Inhibitor Market
23.1. France PCSK9 Inhibitor Market, Segmentation By Drug Type, Segmentation By Route of Administration, Segmentation By Modality, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
24. Italy PCSK9 Inhibitor Market
24.1. Italy PCSK9 Inhibitor Market, Segmentation By Drug Type, Segmentation By Route of Administration, Segmentation By Modality, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
25. Spain PCSK9 Inhibitor Market
25.1. Spain PCSK9 Inhibitor Market, Segmentation By Drug Type, Segmentation By Route of Administration, Segmentation By Modality, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
26. Eastern Europe PCSK9 Inhibitor Market
26.1. Eastern Europe PCSK9 Inhibitor Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
26.2. Eastern Europe PCSK9 Inhibitor Market, Segmentation By Drug Type, Segmentation By Route of Administration, Segmentation By Modality, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
27. Russia PCSK9 Inhibitor Market
27.1. Russia PCSK9 Inhibitor Market, Segmentation By Drug Type, Segmentation By Route of Administration, Segmentation By Modality, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
28. North America PCSK9 Inhibitor Market
28.1. North America PCSK9 Inhibitor Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
28.2. North America PCSK9 Inhibitor Market, Segmentation By Drug Type, Segmentation By Route of Administration, Segmentation By Modality, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
29. USA PCSK9 Inhibitor Market
29.1. USA PCSK9 Inhibitor Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
29.2. USA PCSK9 Inhibitor Market, Segmentation By Drug Type, Segmentation By Route of Administration, Segmentation By Modality, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
30. Canada PCSK9 Inhibitor Market
30.1. Canada PCSK9 Inhibitor Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
30.2. Canada PCSK9 Inhibitor Market, Segmentation By Drug Type, Segmentation By Route of Administration, Segmentation By Modality, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
31. South America PCSK9 Inhibitor Market
31.1. South America PCSK9 Inhibitor Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
31.2. South America PCSK9 Inhibitor Market, Segmentation By Drug Type, Segmentation By Route of Administration, Segmentation By Modality, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
32. Brazil PCSK9 Inhibitor Market
32.1. Brazil PCSK9 Inhibitor Market, Segmentation By Drug Type, Segmentation By Route of Administration, Segmentation By Modality, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
33. Middle East PCSK9 Inhibitor Market
33.1. Middle East PCSK9 Inhibitor Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
33.2. Middle East PCSK9 Inhibitor Market, Segmentation By Drug Type, Segmentation By Route of Administration, Segmentation By Modality, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
34. Africa PCSK9 Inhibitor Market
34.1. Africa PCSK9 Inhibitor Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
34.2. Africa PCSK9 Inhibitor Market, Segmentation By Drug Type, Segmentation By Route of Administration, Segmentation By Modality, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
35. PCSK9 Inhibitor Market Regulatory and Investment Landscape
36. PCSK9 Inhibitor Market Competitive Landscape And Company Profiles
36.1. PCSK9 Inhibitor Market Competitive Landscape And Market Share 2024
36.1.1. Top 10 Companies (Ranked by revenue/share)
36.2. PCSK9 Inhibitor Market - Company Scoring Matrix
36.2.1. Market Revenues
36.2.2. Product Innovation Score
36.2.3. Brand Recognition
36.3. PCSK9 Inhibitor Market Company Profiles
36.3.1. Sanofi S.A Overview, Products and Services, Strategy and Financial Analysis
36.3.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
36.3.3. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
36.3.4. Regeneron Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
36.3.5. Alnylam Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
37. PCSK9 Inhibitor Market Other Major And Innovative Companies
